News
BlueRock clears key hurdle in Parkinson's stem cell trial
It's a case of so far, so good for BlueRock Therapeutics' first …
19814 items found
News
GB first to approve Roche's subcutaneous Tecentriq
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) …
News
BMS grabs key approval for Reblozyl in MDS
Bristol-Myers Squibb's blockbuster aspirations for Reblozyl have been …
Oncology
Phesi’s Dr Gen Li on unlocking the power of data in oncology
Dr Gen Li, founder and president of Phesi, a provider of AI-powered …
News
Pfizer's tornado-hit plant will soon restart production
Pfizer has confirmed that its Rocky Mount facility in North Carolina, …
Digital
An overview of AI in pharma – Part 2
According to Takeda Pharmaceuticals, the average time taken to …
News
FTC hold raises hope of Amgen/Horizon deal progress
The Federal Trade Commission (FTC) in the US has paused its legal …
Digital
Could #MedThreads become the new #MedTwitter?
Last month, Meta, the tech giant behind Facebook, Instagram, and …
News
Semaglutide scores again, this time in heart failure
The list of benefits for Novo Nordisk's semaglutide keeps getting …
Patients
Mapping the landscape of clinical trial regulation
The COVID-19 pandemic pushed decentralised clinical trials (DCTs) …
News
Aspen taps tech firms for digital Parkinson's trial
Aspen Neuroscience is adding a digital dimension to a study of its …
News
One year on, ABPI asks why IMF hasn't funded any drugs
The Innovative Medicines Fund (IMF), set up in the UK last year to …
Market Access
Metrics for the UK’s VPAG: A work in progress
Just as for previous schemes, metrics are being used to track VPAG, the UK’s voluntary scheme that covers branded medicines pricing and access.
Digital
Sponsored
The AI effect in pharma commercial strategy: From data to re...
Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
Patients
Deep Dive: Patients & Partnerships 2024
IN THIS ISSUE: The 2024 US Presidential race is nearing its end, but what does that mean for pharma?
Digital
Sponsored
How to deal with fragmented data - A $12.9 million challenge
In the age of AI, large data sets – like the treasure trove of customer data most biopharma companies are sitting on – are an invaluable asset.
R&D
From neurosurgery to focused ultrasound: Not if, but when
Therapeutic or focused ultrasound began being applied to neurologic conditions less than a decade ago, but its potential in a wide spectrum of brain applications is high.
Sales & Marketing
Sponsored
Launch Excellence: Moments of Truth
The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns, creating challenges and opportunities.
R&D
Partner Content
Welcome to the Molecular Glue Drug Development Summit!
The Molecular Glue Drug Development Summit is back in January, 2025!
R&D
Partner Content
Welcome to the 6th RNAi-Based Therapeutics Summit!
RNAi-Based Therapeutics Returns!
